| Journal | Neuromodulation : journal of the International Neuromodulation Society |
| Study Type | Randomized Trial |
| Population | Human participants |
Cannabis use disorder affects millions yet lacks FDA-approved medical treatments, creating a significant therapeutic gap. This pilot study explores whether targeted brain stimulation could provide a novel intervention pathway for patients struggling with moderate-to-severe cannabis dependence.
This phase 1 open-label pilot study examined deep repetitive transcranial magnetic stimulation (dTMS) using the H4 coil targeting lateral prefrontal cortex and anterior insula in adults with moderate-to-severe cannabis use disorder. Eighteen participants received 18 sessions of H4 dTMS over four weeks alongside standard care, with primary endpoints focused on feasibility and tolerability rather than efficacy. The H4 coil is already FDA-approved for tobacco use disorder, providing regulatory precedent for substance use applications. As an open-label pilot without control group, this study primarily establishes safety and procedural feasibility rather than therapeutic efficacy.
“While intriguing as a potential non-pharmacological intervention, this early-stage pilot data cannot inform clinical decision-making for my patients with cannabis use disorder. The lack of control group and small sample size means we’re still awaiting meaningful efficacy data.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is deep repetitive transcranial magnetic stimulation (dTMS) and how does it work for cannabis use disorder?
Deep repetitive transcranial magnetic stimulation (dTMS) uses powerful electromagnetic pulses to stimulate specific brain networks involved in addiction. The H4 coil targets the lateral prefrontal cortex and anterior insula, brain regions implicated in substance use disorders and already approved for treating tobacco addiction.
Are there currently any FDA-approved medications for cannabis use disorder?
No, there are currently no FDA-approved medications specifically for treating cannabis use disorder. This represents a significant treatment gap, making novel approaches like dTMS particularly important for addressing this public health problem.
What does the treatment protocol involve for dTMS in cannabis use disorder?
The study protocol consisted of 18 dTMS sessions delivered over four weeks: three weeks of five sessions per week, followed by one week of three sessions. Treatment was provided alongside standard addiction care rather than as a standalone intervention.
Is dTMS safe and well-tolerated for people with cannabis use disorder?
This pilot study specifically evaluated the safety and tolerability of H4 dTMS in adults with moderate-to-severe cannabis use disorder. The researchers measured adverse events and treatment completion rates to assess whether this approach is feasible for this patient population.
What makes this study clinically significant for addiction treatment?
This is a first-in-kind pilot study examining dTMS for cannabis use disorder, addressing a critical treatment gap where no approved medical therapies exist. The study’s high clinical relevance stems from its potential to establish a new evidence-based treatment option for a prevalent substance use disorder.
